Mitsubishi Tanabe Pharma Corporation

Hyogo College of Medicine

Mitsubishi Tanabe Pharmaceutical Company

Janssen Pharmaceutica Nv

Joseph M Palumbo

Tomohiro Yoshimoto

Koubun Yasuda

Violetta I Stone

Toru Kato

Michelle Kramer

Marielle-Henriette Eerdekens

Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.

IL-33 antagonist-containing therapeutic agent for endometriosis

The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.

Compositions and methods for treating or preventing vasomotor symptoms

The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, respectively.

Compositions for treating or preventing vasomotor symptoms

Growing community of inventors

Jersey City, NJ, United States of America

Joseph M Palumbo